D.E. Shaw & Co’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

D.E. Shaw & Co’s Portfolio DICE Stock Details DICE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-323,453	Closed	-$15M	–	4648
2023 Q2	$15M	Sell	323,453 -232,788	-42%	-$8.05M	0.02%	1051
2023 Q1	$15.9M	Sell	556,241 -126,693	-19%	-$3.75M	0.02%	1038
2022 Q4	$21.3M	Buy	+682,934	New	+$22.3M	0.02%	871
2022 Q2	–	Sell	-10,718	Closed	-$205K	–	5941
2022 Q1	$205K	Sell	10,718 -53,428	-83%	-$954K	﹤0.01%	4854
2021 Q4	$1.62M	Buy	+64,146	New	+$1.88M	﹤0.01%	3539

D.E. Shaw & Co's DICE Position: Q3 2023 in Review

D.E. Shaw & Co sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 323,453 shares — an estimated $15M sold.

D.E. Shaw & Co first reported a position in DICE in Q4 2021 and held it in 5 quarters. The position peaked at $21.3M in Q4 2022. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

D.E. Shaw & Co reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
D.E. Shaw & Co sold 323,453 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $15M.
D.E. Shaw & Co first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2021 and held it in 5 quarters.
D.E. Shaw & Co's DICE Therapeutics, Inc. Common Stock position peaked at $21.3M in Q4 2022.
0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on D.E. Shaw & Co's 13F filing for Q3 2023, filed 14 Nov 2023.